Paris, France; 24 February, 2009 –
The European Commission has granted marketing authorisation for Servier’s
Valdoxan® /Thymanax® (agomelatine), the first melatonergic antidepressant for
the treatment of adult patients with major depressive episodes.
“There is still great scope for improved therapies to treat the devastating effects of depression”, said Professor Goodwin from Warneford Hospital, Oxford, United-Kingdom. “Valdoxan is an innovative, new approach to the management of depression that compares favourably to existing treatments. It has proven, sustained efficacy across a wide range of depressed patients, including those who are most severely depressed.”
Seotud lood
OECD värskes aruandes „Health at a Glance 2024“ prognoositakse, et aastaks 2050 on Euroopa Liidus (EL) üle 65-aastaseid inimesi juba kolmandik elanikkonnast. Kui lisada sellele elustiiliga seotud riskitegurid ja sotsiaalmajanduslikud erinevused, on selge, et Euroopa peab kiiresti ajakohastama oma tervishoiusüsteeme, et parandada patsientide elukvaliteeti.